Fenway Community Health Center, Inc.

World's First Viral Giving Campaign Gets a "Remix" for Anniversary, Delivering Aid to Patients' Families and Continuing Fight for a Cure Michael Pitt, Lifelong Friend of Peter Frates, Seeks to Honor Frates' Legacy as Newly Appointed Executive Director of Family Foundation BOSTON, July 31, 2024 /PRNewswire/ -- Ten years ago, Pete Frates braced himself in the outfield of iconic Fenway Park, preparing to be doused with a bucket of ice water. It became perhaps the most enduring image of what is now considered the biggest social media fundraising phenomenon in history – raising a quarter of a billion dollars worldwide for Amyotrophic Lateral Sclerosis (ALS) research, prompting the creation of the now-ubiquitous "donate" button on social platforms, and engaging everyone from President Obama to Taylor Swift. Now, on the 10th anniversary, the Peter Frates Family Foundation is ready to reignite that energy and ice-out ALS for good. On Thursday, Aug. 1, the outfield of Fenway will be in the spotlight again as Pete Frates' family will be joined by former NFL MVP Matt Ryan, members of the Red Sox, Patriots & Bruins, ALS researchers and political dignitaries to pay homage to Frates and the power of a simple act – followed by a coordinated live, Ice Bucket Challenge before fans and cameras designed to spark a new wave, and new generation, of social impact. "My son was a born leader, but even he could not have imagined the power we can unleash with such a simple act," said Nancy Frates, Pete Frates' mother and founder of the Peter Frates Family Foundation. "One bucket of ice led to millions of beautiful tributes, and much more importantly, created a global platform for what had been a largely unknown, underfunded disease." The Ice Bucket Challenge and its unexpected virality ushered in a new era of possibility for fundraising. Resulting advancements in research, treatment and drug development has created an environment in which ALS is now becoming a "livable disease," but one of the unintended consequences has been the increased financial responsibilities placed on patients and their families – as home healthcare services for ALS are not covered by insurance. With this harsh realities in mind, the Frates family, along with NWN Carousel, a leading provider of AI-powered technology solutions, decided to use the 10th anniversary of the Challenge as a call-to-action for people around the world to again lift their phones and take the Challenge. And with a whole new generation of influential social media users driving global trends and conversations on platforms like TikTok, the "2.0" Challenge has even more potential to deliver real impact. To help ensure that happens, the Peter Frates Family Foundation has also appointed its first executive director, Michael S. Pitt. Pitt, who was by Pete Frates' side from the first day of their high school football practice until he passed, brings to the Foundation deep expertise in operational and organizational leadership. He previously worked in sales, management and executive consulting capacities across the healthcare industry, as well as serving as development and performance mindset advisor to student-athletes at Northeastern University. He has also worked alongside U.S. military special operators for the past 13 years, providing team-building and leadership development for high school, collegiate and professional athletic teams. "I want to make sure that Pete Frates is a household name, not just today, but 20, 30, 50 years from now," said Pitt. "The Ice Bucket Challenge that Pete helped to initiate is cemented in pop culture history and was a watershed moment for research, but there are still overwhelming costs of home health care facing today's progressed ALS patients and their families. That's our mission at the Peter Frates Family Foundation, and our work is far from over." In his role as executive director, Pitt will work hand-in-hand with Pete Frates' family. He intends to tackle the unresolved problems of home healthcare costs, as well as challenges of fundraising and growth, with the same tenacious spirit and unbreakable resolve that defined Pete and that binds his family. "Pete and I were both athletes, and that competitive fire is what drives our work at the Foundation," Pitt said. "Growing up, the Frates cared and looked after me like I was one of their own. Now in this role, I feel that same familial connection and responsibility to all the families facing the challenges of living with ALS." To learn more about the Ice Bucket Challenge, or to donate to the Peter Frates Family Foundation, please click here. About the Peter Frates Family Foundation The Peter Frates Foundation is a newly formed 501c3 non-profit with the mission to assist progressed ALS patients and their families with the overwhelming cost of home health care. As the disease of ALS progresses through the patient's body, the employment of specialized and skilled providers is imperative for required level care assuring the stability of the patient as they continue to live in their home surrounded by the love and comfort of family and friends. CONTACT Dan Mazei All Tangled Roots, for the Peter Frates Family Foundation [email protected] SOURCE Peter Frates Family Foundation

BOSTON, April 8, 2024 /PRNewswire/ -- The Jimmy Fund announced today that Boston Red Sox pitcher, Garrett Whitlock, will once again serve as the Jimmy Fund Captain this season. For the second consecutive season, Whitlock will serve as an ambassador, supporting and promoting Dana-Farber Cancer Institute and the Jimmy Fund's mission to defy cancer. The Red Sox have partnered with the Jimmy Fund since 1953, the longest and most successful charitable partnership in sports. As Jimmy Fund Captain, Whitlock will continue this long tradition. Continue Reading Red Sox pitcher Garrett Whitlock named 2024 Jimmy Fund Captain "I am honored to continue serving as the Jimmy Fund Captain," said Whitlock. "I am grateful to play a small part in helping raise awareness for Dana-Farber and the Jimmy Fund as we work toward a world without cancer. I look forward to upholding the longstanding Jimmy Fund partnership that is engrained in all Red Sox players. It is a true honor." In this role Whitlock will attend fundraising events, visit patients, build support, and raise funds for cancer care and research at Dana-Farber. Funds raised through the Jimmy Fund support The Dana-Farber Campaign, the Institute's ambitious, multi-year fundraising effort to prevent, treat, and defy cancer through revolutionary science, extraordinary care, exceptional expertise, and essential opportunities—saving more lives than ever before. "We are thrilled to have Garrett Whitlock as our Jimmy Fund Captain again this year," said Suzanne Fountain, vice president of the Jimmy Fund. "Garrett will have the unique opportunity to build upon his work last year, use his established platform to raise awareness of the Jimmy Fund, and serve as a special ambassador in Red Sox nation, to help in the fight against cancer." Past Jimmy Fund Captains include Nathan Eovaldi, Mitch Moreland, Brock Holt, Pablo Sandoval, Will Middlebrooks, David Ross, Jarrod Saltalamacchia, Daniel Bard, Clay Buchholz, and the late Tim Wakefield. Grassroots community fundraising is the heart and soul of the Jimmy Fund—thousands of people organize bike rides, bake sales, lemonade stands, runs, walks, golf tournaments, dances, auctions, softball games, and more, bringing their communities together to help Dana-Farber save lives. Upcoming Jimmy Fund fundraisers include: Strike Out Cancer with the Jimmy Fund – Red Sox fans can help strike out cancer all season long by pledging a donation of any amount for each Red Sox win this season. Every dollar raised supports extraordinary, compassionate patient care while fueling revolutionary science and new discoveries that give patients everywhere hope for a cancer-free future. Our friends at DraftKings are matching each donation, up to $25,000, doubling your impact! Jimmy Fund Day at Fenway presented by DraftKings - Help the Jimmy Fund give Dana-Farber patients the chance of a lifetime to bat and field at Boston's beloved ballpark on May 18. By donating, fans can help send cancer patients to Fenway for this unforgettable experience, while supporting cancer care and research at Dana-Farber. Jimmy Fund Scooper Bowl® presented by Herb Chambers – The nation's largest all-you-can-eat ice cream festival, will take place at Boston's City Hall Plaza on Tuesday, June 4 through Thursday, June 6. Attendees can sample all of the delicious ice cream and other frozen treats while enjoying live entertainment, games, and more. About the Jimmy Fund The Jimmy Fund is comprised of community-based fundraising events and other programs that, solely and directly, benefit Dana-Farber Cancer Institute's lifesaving mission to provide compassionate patient care and groundbreaking cancer research for children and adults. The Jimmy Fund is an official charity of the Boston Red Sox, the Massachusetts Chiefs of Police Association, the Pan-Mass Challenge, and the Variety Children's Charity of New England. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide. Follow the Jimmy Fund on Facebook, Twitter and Instagram: @TheJimmyFund. SOURCE Dana-Farber Cancer Institute

Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of US$5.40 per Unit for gross proceeds of US$7,472,277. Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at US$7.50 for a period of five years commencing six months from the closing of the Offering. The proceeds from the Offering will be used to advance ProMIS’ lead product candidate, PMN310, into a first-in-human study which the Company plans to commence in 2023, subject to FDA’s acceptance of an Investigational New Drug Application (IND). Proceeds will also support expansion of the Company’s intellectual property portfolio, as well as working capital and general corporate purposes. ProMIS’ lead product candidate, PMN310, is a novel monoclonal antibody that is highly selective for toxic oligomers of amyloid-beta which are found in brains of AD patients. ProMIS believes specific targeting of toxic misfolded proteins may directly address fundamental AD pathology while potentially leading to enhanced efficacy and safety compared to other agents due to reduction of off-target activity. ProMIS’ pipeline also includes PMN267, an antibody against misfolded TDP-43 for ALS, and PMN442 targeting misfolded toxic forms of alpha-synuclein, a driver of MSA. “This is an exceptionally exciting time in Alzheimer’s research,” stated Gail Farfel, Ph.D., Chief Executive Officer of ProMIS. “Our patented platform technology has created an antibody candidate, PMN310, specific to toxic misfolded oligomers known to be present in Alzheimer’s disease, which we believe may have greater therapeutic potential than other agents due to reduction of off-target activity. We plan to initiate our first-in-human study in 2023, subject to FDA’s acceptance of our IND, which will represent a significant milestone for the Company, for our shareholders, and for the Alzheimer’s community.” “ProMIS anticipates submission of an IND application for PMN310 by year-end 2022,” added Eugene Williams, Chairman and Co-Founder. “We are excited to be in a position to capitalize on the recent positive momentum in the Alzheimer’s field and grateful for the continued support of our investors. In the future, we look forward to advancing additional programs with our antibody candidates for ALS, PMN267, and for MSA, PMN442, both of which were created using our proprietary platform to generate antibodies highly selective for toxic misfolded proteins.” The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Jeremy Sclar of WS Development, and Dave Welch of 4-Good Ventures. Ceros Financial Services, Inc. acted as the exclusive placement agent for the sale of Units (the “Placement Agent”). In consideration for the services performed, the Company paid Placement Agent a cash fee equal to 8% of the gross proceeds from the Offering and issued the Placement Agent and its designees placement agent warrants to purchase an aggregate of 69,188 Common Shares. Each placement agent warrant entitles the holder thereof to purchase one Common Share at a price of $6.10 per share for a period of five years commencing six months from the closing of the private placement. The Units were offered by a Placement Agent pursuant to an applicable prospectus exemption under Ontario securities laws and pursuant to exemptions from registration under applicable United States federal and state securities laws. The securities sold in the Offering will be “restricted securities” under applicable United States federal and state securities laws. Closing of the Offering remains subject to the final approval of the Toronto Stock Exchange. This press release shall not constitute an offer to sell, the solicitation of an offer to buy or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the United States Securities Act of 1933, as amended (or applicable state securities laws), and such securities may not be offered or sold absent registration or an applicable exemption from such registration requirements. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the TSX under the symbol PMN. Neither the TSX nor Nasdaq has reviewed and neither accepts responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, ‎‎“forward-looking information”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the ‎use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, ‎‎“is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and ‎phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be ‎achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to targeting of toxic misfolded proteins that may directly address fundamental AD pathology and have greater therapeutic potential due to reduction of off-target activity, the initiation of the Company’s first-in-human study in 2023, ProMIS’ pipeline, the use of net proceeds of the Offering, management’s belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers known to be present in Alzheimer’s disease, which may have greater therapeutic potential due to off-target activity, management’s anticipated submission of an IND for PMN310 by year-end 2022, the progression of earlier stage antibody candidates for ALS (PMN267) and MSA (PMN442) and closing of the Offering remaining subject to the final approval of the TSX. Statements containing forward-looking information are not historical facts but instead represent management's current ‎expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such forward-looking information. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company's most recently filed annual information form available on www.SEDAR.com, and in Item 1A of each of its Form 10 Registration Statement and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, each as filed with the Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information: Visit us at www.promisneurosciences.com Follow us on Twitter or LinkedIn For media inquiries, please contact: Shanti Skiffingtonshanti.skiffington@promisneurosciences.com Tel. 617 921-0808 For Investor Relations, please contact: Stern Investor RelationsSuzanne Messere, Managing Directorsuzanne.messere@sternir.comTel. 212 698-8801